newsfilter
← Latest News
Earnings Call Transcripts·

Green Thumb Industries Q326 Earnings Call - Green Thumb Industries

GTBIF

  • Financial Performance:

    • Third-quarter 2026 revenue reached $324 million, representing an 11% year-over-year increase and a 6% sequential growth from Q2.
    • Normalized EBITDA totaled $89.4 million (27.6% margin), up from $80.2 million (27% margin) in the prior year period; adjusted EBITDA margin remained flat YoY despite pricing pressures.
    • Gross profit was $147 million (45% of revenue), down from 49% YoY, primarily driven by $15.8 million in brand licensing fees; normalized gross margins showed slight improvement.
    • Selling, general, and administrative (SG&A) expenses rose to $122 million (38% of revenue) from $107 million (37% of revenue) last year due to compensation, benefits, and costs associated with 22 new retail stores.
    • GAAP net loss was $4.8 million ($0.02 per share), compared to net income of $23.3 million ($0.10 per share) in the prior year, which included a $42 million one-time gain on intellectual property sales.
    • Cash flow from operations was $58 million, a significant increase from the second quarter, providing liquidity for capital deployment.
    • Cash on hand stood at $316 million; full-year 2026 Capital Expenditures (CapEx) are anticipated at approximately $80 million (excluding real estate), with Q3 CapEx at $20 million.
    • Beginning October 10, 2026, Rhythm Inc. will be consolidated into financial statements rather than using equity method accounting, triggered by the removal of conversion caps on warrants/notes, though ownership percentages and plans to convert remain unchanged.

  • Guidance and Future Outlook:

    • Fourth-quarter revenue is expected to be flat to slightly down sequentially due to ongoing pricing compression in key markets.
    • Long-term outlook hinges on federal regulatory clarity, specifically the rescheduling of cannabis and the resolution of Section 280E tax restrictions, which remain the primary value unlock drivers.
    • Virginia adult-use sales are scheduled to commence July 1, 2027; the company expects a supply/demand imbalance, projecting 12–36 months for market capacity to stabilize.
    • Minnesota adult-use launch dynamics are expected to remain a tailwind through at least Q1 2027, with the business shifting from retail-heavy to wholesale-focused as new stores open.
    • Full-year 2026 CapEx remains on track at ~$80 million, excluding real estate acquisitions, funding organic growth in new markets.
    • Management anticipates significant consumer migration from unregulated hemp products to regulated THC beverages following the December 11, 2026 federal ban on intoxicating hemp.

  • Business Segments and Product Lines:

    • Retail: Revenue grew 10% YoY, led by Minnesota (adult-use launch), Florida, Ohio, Virginia, and Illinois (aided by M&A). Same-store sales for the 108-store base grew 3% YoY, the first positive comparable growth since Q3 2024. Six new RISE dispensaries opened in the quarter; total footprint now exceeds 130 stores, including 27 in Florida.
    • CPG (Consumer Packaged Goods): Revenue grew 16% YoY, driven by Minnesota and strength in Illinois, New Jersey, New York, and Ohio.
    • Brand Performance: "Rhythm" ranks #1 nationally in branded flower; "Dog Walkers" ranks #1 nationally in uninfused pre-rolls and marks its 10-year anniversary.
    • Capital Allocation: The board authorized a new $50 million share repurchase program in September; since Q4 2023, the company has returned over $200 million (29.5 million shares) to shareholders.
    • New Markets: Significant investments made in Virginia (6 retail, 2 cultivation) and Texas (wholesale hub acquired); Texas expansion pace depends on hemp/federal policy clarity.

  • Market and Competitive Landscape:

    • The industry faces persistent pricing pressure and competition in multiple states, yet the company maintains #1 market positions in key jurisdictions including Illinois, Maryland, and New Jersey.
    • Cannabis is increasingly competing directly with alcohol and CPG giants; the company views THC beverages as a viable fourth adult beverage category, gaining traction with major retailers and entertainment venues.
    • Federal regulatory uncertainty remains the "single biggest wild card," with 280E relief for medical cannabis pending as a priority for the IRS in fiscal 2027.
    • Market consensus suggests a multi-year biomass shortage in new markets like Virginia, though the company has excess capacity ready to deploy.
    • Management notes that uplisting alone does not unlock value; institutional interest requires federal certainty on taxes and scheduling.

  • Risks and Challenges:

    • Federal Regulation: Ongoing uncertainty regarding the rescheduling of cannabis and the interpretation of Section 280E tax code poses significant valuation and liability risks.
    • Hemp Legislation: The December 11, 2026, federal ban on intoxicating hemp products creates immediate supply chain disruption and consumer transition risks.
    • Pricing Compression: Continued price erosion in various markets threatens gross margins, requiring offsetting volume growth and operating discipline.
    • Regulatory Scenarios: State-level regulatory shifts, such as the Texas Compassionate Use Program (TCOP) following recent elections, introduce uncertainty regarding market entry timing and license conditions.
    • Supply Chain: Potential biomass shortages in new states could delay adult-use market saturation and revenue realization.

  • Management Commentary and Tone:

    • CEO Ben Kobler emphasized that navigating regulatory uncertainty is a "core competency," highlighting the company's focus on brand building, team investment, and balance sheet protection.
    • Management expressed confidence in the "unrecognized value" of the business, stating that federal clarity will be the primary catalyst for unlocking market valuation.
    • The tone regarding share buybacks and M&A was cautious yet opportunistic, prioritizing clarity on the tax landscape before aggressive deployment of capital.
    • Management dismissed the idea of bifurcating the business (splitting medical from adult-use), citing operational complications and lack of viable buyers for a standalone medical entity without market multiples.
    • Strong emphasis was placed on the consumer shift toward regulated THC beverages as the industry adapts to the impending hemp ban.

  • Analyst Questions and Answers:

    • Texas Market Impact: Anthony Georgiatis noted that the recent Texas gubernatorial election results are still being digested; the company is evaluating potential impacts on the TCOP program but remains prepared to partner with the new administration.
    • Capital Allocation Priority: Management reiterated a preference for organic growth (Virginia, Texas, Florida) and share buybacks over M&A until tax clarity improves, though M&A remains an option if valuations become attractive.
    • Virginia Supply Dynamics: Anthony projected a 12–36 month timeline for Virginia to absorb anticipated demand due to biomass constraints, similar to the trajectory seen in Minnesota.
    • Minnesota Transition: Ben Kobler and Anthony clarified that Minnesota's business will pivot toward wholesale as the retail network expands, leveraging existing brands to supply new operators.
    • Rescheduling and Upslisting: Ben Kobler declined to speculate on the timing of federal rescheduling post-election and reiterated that uplisting the medical business is not currently a priority given the lack of institutional buyers for standalone medical assets.
    • Hemp Ban Behavior: Ben Kobler confirmed significant "pantry loading" by consumers and retailers ahead of the December 11 hemp ban, creating a temporary surge in sales and channel displacement toward regulated dispensaries.

  • Other Key Points:

    • Massachusetts voters rejected a proposal to ban adult-use cannabis, with over 75% voting to keep the program in place.
    • The company views the current market as a $30–$40 billion opportunity (potentially $50 billion with hemp), where it currently holds only 2–5% share.
    • Tax timing is critical; delays in 280E resolution could extend significant tax liabilities, though medical operations are already exempt.
    • Management plans to return to Q4 results and year-end outlook in early 2027, describing the next 120 days as a "critical" period for regulatory developments.